Investor Relations

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s healthy cells and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with approved cancer treatments to unlock the power of combination therapy.

2016 Annual Meeting

0.00 (0.00%)
4:00 PM ET on Mar 28, 2017
Delayed at least 20 minutes.
Shareholder Tools